![]() |
|
|
Vol. 301, Issue 1, 315-321, April 2002
Departments of Pediatrics and Pharmacology, Case Western Reserve
University, Division of Pediatric Pharmacology and Critical Care,
Rainbow Babies and Children's Hospital of the University Hospitals of
Cleveland, Cleveland, Ohio
Dopamine and dobutamine are often infused together into acutely
ill patients requiring temporary support of cardiac and renal function,
but whether these catecholamines affect the metabolic clearance of each
other is not established. We determined the kinetics of dopamine and
dobutamine as substrates and inhibitors of each other, i.e., apparent
Vmax, Km, and
Ki, with crude preparations of human blood
mononuclear cell catechol-O-methyltransferase
(COMT) and platelet monoamine oxidase (MAO) at pH 7.4 and
37°C. Values of Vmax for
dopamine and dobutamine as substrates for COMT were 0.45 and 0.59 nmol
of 3-O-methyl product formed per milligram of protein per
minute, whereas those for Km were 0.44 and 0.05 mM, respectively. Dopamine and dobutamine were competitive
inhibitors of each other in this reaction. The
Ki for dopamine as an inhibitor of
dobutamine methylation was 1.5 mM, whereas that for dobutamine as an
inhibitor of dopamine methylation was 0.015 mM. Dopamine but not
dobutamine was a substrate for MAO. The
Vmax for dihydroxyphenylacetaldehyde formation from dopamine was 0.29 nmol/mg protein/min and the
Km for dopamine was 0.38 mM.
Dobutamine was a noncompetitive inhibitor of dopamine oxidation in this
reaction (Ki
1.19 mM). The high apparent Km and
Ki values derived for dopamine and
dobutamine when tested with these two human enzymes in vitro suggest
that these catecholamines do not interfere with the metabolism of each other when both are infused together at therapeutic concentrations.